EU GMP Annex 11 (Computerised Systems) is the European equivalent of FDA 21 CFR Part 11 but with important differences in scope and emphasis. Annex 11 applies to all computerized systems used in GMP-regulated activities including CMMS that manages equipment maintenance records, calibration schedules, and corrective and preventive actions (CAPA).
Key Annex 11 requirements relevant to CMMS: Validation, all computerized systems must be validated according to a risk-based approach; the extent of validation should reflect the system's impact on product quality and patient safety.
Data integrity, the ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available) apply to all GMP records including CMMS-generated maintenance data.
Audit trails, must be enabled and reviewed regularly; CMMS audit trails should capture who made which change, when, and why. Supplier assessment, the pharmaceutical manufacturer must evaluate CMMS vendors' quality systems and obtain appropriate evidence of software development process quality (typically via audit or questionnaire). Business continuity, the system must remain available during GMP operations with defined backup and recovery procedures.
Good Automated Manufacturing Practice (GAMP 5) provides the risk-based framework that EU pharma manufacturers use to scale validation effort appropriately. CMMS software typically falls into GAMP Category 4 (configured products), standard commercial software customized through configuration rather than code modification. Category 4 validation requires supplier assessment, installation qualification, operational qualification, and performance qualification, but the testing burden is lower than Category 5 (custom software).
The validation strategy for CMMS should be documented in a Validation Plan before deployment begins and should cover: risk assessment of CMMS functions and their impact on product quality, test script development covering critical functions (work order creation, PM schedule execution, audit trail generation, electronic signature), and a performance qualification covering the actual manufacturing environment.
European pharmaceutical manufacturers must also comply with EudraLex Volume 4 Chapter 4 (Documentation) requirements for electronic records, which align with Annex 11 but include additional requirements around document management that affect how CMMS records are managed long-term.
European pharmaceutical manufacturers should require these deliverables from any CMMS vendor under consideration for GMP-regulated environments. Supplier Questionnaire response: a completed quality systems questionnaire covering software development process (following GAMP 5 or equivalent), change control process, security practices, and support capabilities.
Software Development Lifecycle documentation: evidence of requirements management, design documentation, testing records, and change control for software releases. Data center audit evidence or certification: for cloud CMMS, ISO 27001 certification and SOC 2 Type II report are baseline; EU pharma manufacturers may require right-to-audit clauses for cloud infrastructure.
Validation package: IQ protocol templates, OQ test scripts covering Annex 11 requirements, and PQ scenario templates for the manufacturer to execute. Long-term record retention: EU GMP requires records to be retained for the lifetime of the product plus a specified period. CMMS data retention capability and export format should be contractually specified.
Service level agreement: CMMS availability requirements should be specified in the SLA with defined remediation for availability failures that affect GMP operations. Annex 11 compliance is a partnership between the manufacturer and the vendor, vendors who treat this as a checkbox rather than a shared obligation are a compliance risk.
Login
Blog
